Chutko, L S, Surushkina, S Yu, Yakovenko, E A et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2024 · DOI
Quick Summary
This article reviews existing research on ME/CFS (chronic fatigue syndrome) in children. The authors summarize what scientists have learned about how common the condition is, what causes it, how doctors diagnose it, and what treatments might help. A major focus is on cognitive problems—like difficulty concentrating and brain fog—that children with ME/CFS often experience.
Why It Matters
ME/CFS significantly impacts children's quality of life, school attendance, and development. Understanding the disease's epidemiology, clinical features unique to children, and cognitive effects is essential for earlier recognition and improved management. This consolidated overview of current research may help clinicians better diagnose and treat affected children.
Observed Findings
ME/CFS occurs in both children and adults with documented epidemiological patterns
Multiple theories exist regarding etiology and pathogenic mechanisms of ME/CFS
Children with ME/CFS show specific clinical manifestations distinct from adults
Neurocognitive deficits are a documented feature of pediatric ME/CFS
Various therapeutic approaches have been explored in research literature
Inferred Conclusions
ME/CFS in children requires recognition of age-specific clinical and cognitive features for proper diagnosis
Multiple etiological pathways may contribute to ME/CFS development
Cognitive dysfunction is a significant component of pediatric ME/CFS that warrants clinical attention
Therapeutic research in pediatric ME/CFS is ongoing and shows varied approaches
Remaining Questions
Which etiological mechanisms are primary versus secondary in pediatric ME/CFS?
What are the most effective evidence-based treatments for children with ME/CFS?
What This Study Does Not Prove
This review does not establish definitive causes of ME/CFS or prove the efficacy of specific treatments—it summarizes what others have published. The conclusions are limited by the quality and scope of underlying studies reviewed. It does not provide new experimental data or test new therapeutic interventions.